

AGENDA ITEM	FINDINGS OR CONCLUSION	ACTION, RESPONSIBILITY	STATUS
Medication Use	<ol style="list-style-type: none"> Pharmacist-driven 4T score calculation for streamlining HIT lab tests: Andrea Wilkinson, pharmacy resident, presented her MUE results which demonstrated that by calculating a 4T score for all orders, pharmacists played a role in decreasing heparin antibody tests being performed in patients unlikely to have HIT (low 4T scores). Additional pharmacist education on the 4T score calculation will be provided, as there is opportunity to improve calculation accuracy because 78% of the orders sent to lab still resulted in negative heparin antibody tests. The committee discussed upcoming plans to send all HIT Ab and SRA tests to Erlanger (instead of Quest) for faster result turnaround time. Collagenase (Santyl®) ointment: Rachel shared MUE results on inpatient collagenase ointment utilization. From May through December 2020, Santyl dispensed from the inpatient pharmacy had a total drug cost of ~\$43,000. Based on the MUE results, it was recommended to adopt the CHI approved restriction criteria for use, which will be built into the EHR. This recommendation was previously reviewed and supported by Dr. John Gwin. Tocilizumab (Actemra®) for Inpatient Treatment of COVID-19: A P&T subcommittee convened earlier in the week to review available clinical data on tocilizumab (Actemra®) in COVID-19 and determine criteria for appropriate use. Rachel reviewed the locally designated restriction criteria finalized by the subcommittee, which will be updated as needed based on available data. 	<p>Informational</p> <p>Approved</p> <p>Approved</p>	<p>Complete</p> <p>Complete</p> <p>Complete</p>
Protocols & Orders	<ol style="list-style-type: none"> Respiratory Distress Orders Policy (Protocol): Kevin Hopkins presented changes to the policy which will allow oxygen, bronchodilators, and arterial blood gas orders to be placed by respiratory therapists, per protocol, with physician co-signature required in the EHR. This policy will be added to the list of protocols reviewed annually per TJC requirements. 	<p>Approved</p>	<p>Complete</p>
Policies	<ol style="list-style-type: none"> Titrating Medications: This policy was updated to include dosing (titrating) instructions for nitroglycerin infusions on cardiac telemetry floors. No other changes to this policy. Look-Alike Sound-Alike Medications: This policy was reviewed and no changes were needed. 	<p>Approved</p> <p>Approved</p>	<p>Complete</p> <p>Complete</p>
Nutrition	<ol style="list-style-type: none"> Nutrition Care Manual: Susan Fuchs reviewed the changes made for the November 2020 update. The manual can be found on the Mnet under "Clinical Tools". Enteral Policy: Susan reviewed policy changes which included verbiage update to reflect the EHR transition, in addition to RD managed enteral nutrition ordering workflow(s). 	<p>Approved</p> <p>Approved</p>	<p>Complete</p> <p>Complete</p>

There being no further business, the meeting was adjourned at 8:00 a.m. The next P&T meeting is **April 15, 2021 at 7:00 a.m.**

Respectfully submitted,
Patrick N. Ellis, PharmD, Director of Pharmacy
Rachel Kile, PharmD, Pharmacy Clinical Manager

Approved by,
Nathan Chamberlain, MD, Chairman